ArticleFrontiers in bioinformatics2026
Rational discovery of peptide inhibitors targeting Keap1: a focus on neurodegenerative diseases.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Kelch-like ECH-associated protein 1 (Keap1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a promising therapeutic target for neurodegenerative diseases (NDDs). Nrf2 activation mitigates key pathogenic mechanisms in NDDs by enhancing antioxidant defenses, suppressing neuroinflammation, improving mitochondrial function, inhibiting ferroptosis, and maintaining proteostasis. Aim: To design and identify peptide inhibitors capable of disrupting the Keap1/Nrf2 interaction through a rational computational approach. Methods: A combinatorial peptide library comprising 13,167 peptides was generated from an Nrf2-derived template peptide and subjected to rigorous multi-tier screening based on predicted blood-brain barrier permeability, toxicity, allergenicity, antioxidant and anti-inflammatory potential, and physicochemical properties. Following comprehensive safety assessments, 11 promising peptides were shortlisted and evaluated using molecular docking, MM-GBSA binding free-energy calculations, and per-residue energy decomposition analysis. The top-ranked peptide candidates were subsequently subjected to 200 ns molecular dynamics (MD) simulations to assess complex stability and binding behavior through analyses of structural stability, flexibility, principal component analysis (PCA), hydrogen-bond occupancy, and free-energy landscape analyses. Results: Among the shortlisted peptides, LMEETYEFL (pep4369) and LDYETYEFL (pep6649) exhibited stronger binding affinities toward Keap1 than the template peptide in docking and MM-GBSA analyses. MD simulations confirmed the structural stability and favorable conformational behavior of the peptide-Keap1 complexes throughout the simulation period. Conclusion: These findings suggest that LMEETYEFL and LDYETYEFL are promising candidates for disrupting the Keap1/Nrf2 interaction. However, experimental validation is necessary to confirm their therapeutic potential and facilitate further biological evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.